AB-PINACA

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication.

AB-PINACA acts as a potent agonist for the CB 1 receptor (K i = 2.87 nM, EC 50 = 1.2 nM) and CB 2 receptor (K i = 0.88 nM, EC 50 = 2.5 nM) and fully substitutes for Δ 9 -THC in rat discrimination studies, while being 1.5x more potent. There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.

AB-PINACA is a compound that was first identified as a component of synthetic cannabis products in Japan in 2012. It was originally developed by Pfizer in 2009 as an analgesic medication.

AB-PINACA acts as a potent agonist for the CB 1 receptor (K i  = 2.87 nM, EC 50  = 1.2 nM) and CB 2 receptor (K i  = 0.88 nM, EC 50  = 2.5 nM) and fully substitutes for Δ 9 -THC in rat discrimination studies, while being 1.5x more potent. There have been a number of reported cases of deaths and hospitalizations in relation to this synthetic cannabinoid.

Germany

AB-PINACA is an Anlage II controlled substance in Germany as of November 2014.

Singapore

It is listed in the Fifth Schedule of the Misuse of Drugs Act and so is illegal in Singapore, as of May 2015.

United States

It is a Schedule I controlled substance in the United States.

China

It is a controlled substance in China as of October 2015.

France

It is a controlled substance in France as of March 2017.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1370536455 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

8 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.